GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Eagle Pharmaceuticals EGRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.82

-8.89%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Eagle Pharmaceuticals — daily EGRX Delayed
Market value
$10.7m
Last close × shares
Volume
905
Shares, 9 Nov 2026
Price to earnings
0.1

About Eagle Pharmaceuticals

Its shares trade under the ticker EGRX. It has been listed since 12 February 2014. In the fiscal year to 31 December 2022, it reported revenue of $316.6m and net income of $35.6m. At that date it held total assets of $406.2m and shareholders' equity of $233.6m.

Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. The company is headquartered in Woodcliff Lake, New Jersey. The company went IPO on 2014-02-12. The firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The firm's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Figures and description from our data supplier, not checked against the company's own report.

More about Eagle Pharmaceuticals →

How it makes its money

Revenue, year to 31 Dec 2022

  • Product sales, net $214.5m · 67.8%
  • Royalty revenue $98.3m · 31.0%
  • PEMFEXY $67.5m · 21.3%
  • Vasopressin $63.2m · 19.9%

Latest on Eagle Pharmaceuticals

Our reporting

We have not reported on Eagle Pharmaceuticals yet.

Next results

9 Nov 2026

Due on 9 Nov 2026. Analysts expect earnings of 0.73 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Eagle Pharmaceuticals's ticker?

Eagle Pharmaceuticals trades as EGRX on its US listing, under ISIN US2697961082.

What was Eagle Pharmaceuticals's last closing price?

0.82 on 9 Nov 2026. The figure is in USD and is never converted.

When does Eagle Pharmaceuticals next report results?

Results are expected on 9 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.